Focused, efficient drug developers
We are experienced drug developers with particular expertise in VEGF biology advancing towards a clearly defined goal: to help sufferers of the rare disease LAM.
We are a proud product of Australian science and Australian investment and have built a lean team to advance CYV-101 in a disciplined way through clinical development.
Management
Scientific Advisory Board
We have brought together global thought leaders in LAM with decades of clinical experience and patient collaboration to inform our development efforts.
